Aclaris Therapeutics Announces Participation in March Conferences

Author: Olivia Taylor Updated: 03-04-2025 07:14 AM

Aclaris Therapeutics Engages with Healthcare Community

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for immuno-inflammatory diseases, is excited to announce its participation in two significant healthcare conferences scheduled for this March.

Upcoming Conference Participation Details

On Tuesday, March 11, 2025, at 3:00 PM EDT, Dr. Neal Walker, the Chief Executive Officer of Aclaris, along with other key members of the senior leadership team, will engage in a fireside chat during the Leerink Partners Global Healthcare Conference, taking place in a vibrant Miami setting.

The Importance of the Leerink Conference

This conference serves as a critical platform, not only for Aclaris to showcase its innovative pipeline but also to foster discussions about the future of treatment in immuno-inflammatory conditions. The interactions here are invaluable, allowing stakeholders from diverse backgrounds to connect and collaborate.

Virtual Fireside Chat on Autoimmune Diseases

Following that, on Thursday, March 27, 2025, at 9:00 AM EDT, Dr. Walker and his leadership team will partake in a virtual fireside chat during the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. This virtual setup enables greater participation from an audience that may otherwise be unable to attend in person.

What to Expect During the Talk

During this engaging discussion, Aclaris plans to discuss its innovative approaches to tackling the unmet needs in treating autoimmune and inflammatory diseases. They'll delve into the company’s ongoing research and potential to revolutionize care.

Accessing the Conference Webcasts

For those interested in learning more about Aclaris Therapeutics and its future directions, live and archived webcasts for both events will be available on Aclaris’ events page. They will remain accessible on the company’s website for at least 30 days post-event, ensuring a broad audience can benefit from the insights shared.

About Aclaris Therapeutics

Aclaris Therapeutics aspires to redefine the treatment paradigm for patients grappling with immuno-inflammatory diseases through its broad scope of innovative product candidates. The company prides itself on its robust research and development capabilities, supporting its commitment to meeting the diverse needs of patients.

Company Vision and Commitment

Aclaris remains steadfast in its goal: to deliver effective treatment alternatives that can significantly improve the quality of life for patients. Future developments in their portfolio are awaited with great interest by both the medical community and patients alike.

Contact Information for Aclaris Therapeutics

For further inquiries regarding Aclaris Therapeutics, please reach out to:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

Frequently Asked Questions

What is Aclaris Therapeutics focused on?

Aclaris Therapeutics specializes in developing innovative solutions for immuno-inflammatory diseases.

When is Aclaris participating in the Leerink Conference?

Aclaris is presenting on March 11, 2025, at 3:00 PM EDT.

What formats will the conference be available in?

The conferences will be available via live webcasts and recorded for later viewing.

Who are the key speakers from Aclaris?

Dr. Neal Walker will be the primary speaker, representing the senior leadership team.

How can I follow Aclaris Therapeutics for updates?

You can keep up with Aclaris through their official website and social media platforms.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.